BE2012C005I2 - - Google Patents

Download PDF

Info

Publication number
BE2012C005I2
BE2012C005I2 BE2012C005C BE2012C005C BE2012C005I2 BE 2012C005 I2 BE2012C005 I2 BE 2012C005I2 BE 2012C005 C BE2012C005 C BE 2012C005C BE 2012C005 C BE2012C005 C BE 2012C005C BE 2012C005 I2 BE2012C005 I2 BE 2012C005I2
Authority
BE
Belgium
Prior art keywords
blys
antibodies
present disclosure
related molecules
immunospecifically bind
Prior art date
Application number
BE2012C005C
Other languages
English (en)
French (fr)
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27539647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2012C005(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of BE2012C005I2 publication Critical patent/BE2012C005I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
BE2012C005C 2000-06-16 2012-01-12 BE2012C005I2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21221000P 2000-06-16 2000-06-16
US24081600P 2000-10-17 2000-10-17
US27624801P 2001-03-16 2001-03-16
US27737901P 2001-03-21 2001-03-21
US29349901P 2001-05-25 2001-05-25
PCT/US2001/019110 WO2002002641A1 (en) 2000-06-16 2001-06-15 Antibodies that immunospecifically bind to blys

Publications (1)

Publication Number Publication Date
BE2012C005I2 true BE2012C005I2 (de) 2020-08-20

Family

ID=27539647

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2012C005C BE2012C005I2 (de) 2000-06-16 2012-01-12

Country Status (19)

Country Link
US (4) US7138501B2 (de)
EP (4) EP2281843B1 (de)
JP (2) JP4902087B2 (de)
KR (4) KR20120053525A (de)
CN (1) CN1279055C (de)
AT (1) ATE494304T1 (de)
AU (3) AU2001268427B2 (de)
BE (1) BE2012C005I2 (de)
CA (1) CA2407910C (de)
CY (4) CY1112793T1 (de)
DE (1) DE60143798D1 (de)
DK (1) DK1294769T3 (de)
ES (3) ES2609583T3 (de)
FR (1) FR12C0001I2 (de)
LU (1) LU91926I2 (de)
MX (1) MXPA02012434A (de)
NZ (1) NZ522700A (de)
PT (2) PT2275449T (de)
WO (1) WO2002002641A1 (de)

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
PL198934B1 (pl) 1999-01-25 2008-08-29 Apoxis Sa Zastosowanie przeciwciała swoistego wobec rozpuszczalnego BAFF lub aktywnego fragmentu przeciwciała i zastosowanie rozpuszczalnego BAFF lub jego aktywnego fragmentu
EP2204186B1 (de) 1999-02-17 2016-04-06 CSL Limited Immunogene Komplexe und damit zusammenhängende Verfahren
EP1806143B1 (de) 1999-08-17 2016-06-15 Biogen MA Inc. BAFF-Rezeptor (BCMA), ein immunregulatorischer Wirkstoff
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR20120053525A (ko) * 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002016411A2 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EP2270040A3 (de) * 2000-08-18 2011-07-06 Human Genome Sciences, Inc. Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
CA2426710A1 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
DE60144063D1 (de) 2000-12-18 2011-03-31 Dyax Corp Gerichtete bibliotheken die genetisch verpackt sind
CA2447832C (en) * 2000-12-22 2012-09-25 Jamshid Tanha Phage display libraries of human vh fragments
WO2002094192A2 (en) * 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
ES2437992T3 (es) * 2001-05-25 2014-01-15 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
EP1425694A2 (de) 2001-08-03 2004-06-09 Medical Research Council Verfahren zur identifizierung der konsensus-sequenz von intrazellulären antikörpern
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
US7112410B1 (en) * 2001-08-29 2006-09-26 Human Genome Sciences, Inc. Human tumor necrosis factor TR21 and methods based thereon
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US20030157522A1 (en) * 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
EP1456347A4 (de) * 2001-11-16 2006-08-02 Human Genome Sciences Inc Immunspezifisch an blys bindende antikörper
US20060210555A1 (en) * 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
WO2003064606A2 (en) * 2002-01-28 2003-08-07 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
AU2003234706A1 (en) * 2002-04-15 2003-11-03 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
US7456260B2 (en) 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2491669A1 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
WO2004013287A2 (en) 2002-08-02 2004-02-12 Human Genome Sciences, Inc. Antibodies against c3a receptor
BR0316197A (pt) * 2002-11-12 2005-09-27 Becton Dickinson Co Kit, perfil biomarcador e método de isolar um biomarcador de resposta de hospedeiro
CN100543135C (zh) * 2003-02-28 2009-09-23 田边三菱制药株式会社 单克隆抗体及编码其的基因、药物组合物和诊断试剂
EP1598419A1 (de) * 2003-02-28 2005-11-23 Mitsubishi Pharma Corporation Monoklonaler antikörper, dafür codierendes gen, hybridom, medizinische zusammensetzung und diagnostikum
ATE456581T1 (de) * 2003-03-14 2010-02-15 Wyeth Corp Antikörper gegen il21-rezeptor und deren verwendung
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
KR100988129B1 (ko) * 2003-04-30 2010-10-18 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 인간 항인간 인터루킨-18 항체와 그 단편, 및 이들의이용방법
EP1629001A2 (de) 2003-06-05 2006-03-01 Genentech, Inc. Blys-antagonisten und deren verwendung
EP3011971B1 (de) 2003-06-27 2021-07-21 Amgen Fremont Inc. Auf die deletionsmutanten des epidermalen wachstumsfaktorrezeptors gerichtete antikörper und verwendungen davon
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
CA2545893A1 (en) * 2003-11-14 2005-06-02 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
CA2554526A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CA2563024C (en) * 2004-03-30 2015-02-03 Canadian Blood Services Method for treating autoimmune diseases with antibodies
KR100924044B1 (ko) * 2004-03-31 2009-10-27 캐논 가부시끼가이샤 표적 물질 포착 구조체
JPWO2005105998A1 (ja) * 2004-04-27 2008-07-31 財団法人化学及血清療法研究所 ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
WO2005108986A1 (en) * 2004-05-10 2005-11-17 Korea Research Institute Of Bioscience And Biotechnology A diagnostic method of asthma using baff as a diagnostic marker
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP5570681B2 (ja) * 2004-08-31 2014-08-13 興和株式会社 抗ヒトｂａｆｆ抗体
WO2006039470A2 (en) * 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
EP1855711B1 (de) * 2005-01-28 2009-06-17 Biogen Idec MA Inc. VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
AU2011247831B8 (en) * 2005-03-25 2014-02-20 National Research Council Of Canada Method for isolation of soluble polypeptides
EP2368992A3 (de) 2005-03-25 2012-03-14 National Research Council Of Canada Verfahren zur Isolierung von löslichen Polypeptiden
EP1869463A4 (de) 2005-04-15 2010-05-05 Becton Dickinson Co Sepsisdiagnose
US20060240006A1 (en) * 2005-04-20 2006-10-26 Chishih Chu Novel antibody structures derived from human germline sequences
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
CA2640066A1 (en) * 2006-01-24 2007-08-02 Roland Beckmann Fusion proteins that contain natural junctions
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
JP2007306828A (ja) * 2006-05-17 2007-11-29 Tokai Univ 非還元マンノース残基を認識するファージ提示型単鎖抗体
AU2007256639A1 (en) * 2006-06-07 2007-12-13 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US7981417B2 (en) * 2006-06-07 2011-07-19 Wisconsin Alumni Research Foundation Blood-brain barrier targeting anti-bodies
EP2975057A1 (de) * 2006-07-10 2016-01-20 Fujita Health University Neuer anti-cd73 antikörper
CL2007002926A1 (es) * 2006-10-12 2008-05-16 Genentech Inc Anticuerpo antilinfotoxina alfa (lt-alfa); composicion con el anticuerpo; hibridoma pta-7538; acido nucleico codificante del anticuerpo; vector y celula huesped que comprenden el acido nucleico; metodo para inhibir la proliferacion celular activada p
WO2008140483A2 (en) * 2006-11-09 2008-11-20 Human Genome Sciences, Inc. Methods and antibodies for detecting protective antigen
DK2104682T3 (en) * 2007-01-11 2017-01-16 Michael Bacher DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES
EP2164869A2 (de) * 2007-05-31 2010-03-24 Merck Sharp & Dohme Corp. Auf s. aureus orf0657n abzielende antigenbindende proteine
CL2008002153A1 (es) * 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
CA2695237A1 (en) * 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
US8906844B2 (en) 2007-08-09 2014-12-09 Biogen Idec Hemophilia Inc. Immunomodulatory peptides
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
ES2565202T3 (es) 2007-10-16 2016-04-01 Zymogenetics, Inc. Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
EP2535353A1 (de) * 2007-11-13 2012-12-19 Evec Inc. An hGM-CSF bindende monoklonale Antikörper und medizinische Zusammensetzungen damit
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
AU2009237662A1 (en) * 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
HUE028784T2 (en) 2008-05-01 2017-01-30 Zymogenetics Inc Serum levels and use of BLYS / APRIL heterotrimers in diagnostic procedures
ES2595362T3 (es) 2008-06-16 2016-12-29 Patrys Limited Anticuerpos LM, fragmentos funcionales, antígeno diana LM-1 y métodos para prepararlos y usarlos
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20110057245A (ko) * 2008-09-19 2011-05-31 메디뮨 엘엘씨 Ｃｄ105에 대해 지시된 항체 및 그의 용도
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
MX2011005481A (es) * 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
KR20110138412A (ko) * 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 항-ΤΝＦ-α 항체 및 그의 용도
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
EP3211094A3 (de) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Verfahren zur behandlung, diagnose und überwachung rheumatoider arthritis
KR20190047135A (ko) 2010-03-01 2019-05-07 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
EP2582392A4 (de) * 2010-06-18 2015-02-18 Human Genome Sciences Inc Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur behandlung von asthma und anderer allergie- oder entzündungsleiden des atemsystems
RU2598711C2 (ru) 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения
JP6012605B2 (ja) 2010-09-22 2016-10-25 アリオス バイオファーマ インク． 置換されたヌクレオチドアナログ
US8394378B2 (en) 2010-09-27 2013-03-12 Janssen Biotech, Inc. Antibodies binding human collagen II
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
CA2824997C (en) * 2011-01-18 2023-01-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
KR102042982B1 (ko) * 2011-07-22 2019-11-11 체에스엘 베링 게엠베하 억제성 항-ｘｉｉ/ｘｉｉａ 인자 모노클로날 항체 및 이들의 사용
EP2741770A4 (de) * 2011-08-09 2014-12-31 Athera Biotechnologies Ab Antikörperbindung an phosphorylcholin (pc) und/oder pc-konjugate
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US10745468B2 (en) * 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US10233424B2 (en) * 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US9512212B2 (en) * 2012-01-11 2016-12-06 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
EP2828277A1 (de) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Feste formen eines thiophosphoramidat-nucleotid-prodrugs
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2833918B1 (de) * 2012-04-05 2019-05-08 Massachusetts Institute of Technology Immunstimulationszusammensetzungen und verfahren zur verwendung davon
CN103421113B (zh) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
WO2014062245A2 (en) * 2012-05-31 2014-04-24 Sorrento Therapeutics Inc. Antigen binding proteins that bind dll-4
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
KR102134088B1 (ko) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
EP2895512B1 (de) * 2012-09-12 2018-07-04 Neurimmune Holding AG Gegen das menschliche insel-amyloid-polypeptid (hiapp) spezifische antikörper und verwendungen davon
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
EP2970500A1 (de) 2013-03-14 2016-01-20 Bayer HealthCare LLC Monoklonale antikörper gegen mit heparin komplexiertes beta-antithrombin
PT3508502T (pt) 2013-09-20 2023-06-22 Bristol Myers Squibb Co Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
ES2729057T3 (es) 2013-12-17 2019-10-30 Aimm Therapeutics Bv Medios y métodos para contrarrestar trastornos mieloproliferativos o linfoproliferativos
US9683048B2 (en) 2014-01-24 2017-06-20 Novartis Ag Antibody molecules to PD-1 and uses thereof
CN104804091B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及用途
CN104804090B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体和用途
CN104804092B (zh) * 2014-01-29 2018-03-27 天津胜发生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及其用途
CA2934965A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
JP6576962B2 (ja) 2014-03-14 2019-09-18 ノバルティス アーゲー Ｌａｇ−３に対する抗体分子およびその使用
WO2015191583A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191590A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
WO2015191596A1 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
WO2015191617A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
WO2015191615A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
WO2015191568A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US10758526B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
US11033621B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
WO2016032949A1 (en) 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
SMT202100221T1 (it) 2014-12-05 2021-07-12 Memorial Sloan Kettering Cancer Center Anticorpi bersaglianti l'antigene di maturazione delle cellule e metodi d'uso
CN113683711A (zh) 2014-12-05 2021-11-23 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
NZ732570A (en) 2014-12-05 2022-12-23 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
WO2016098356A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
CN112142844B (zh) 2015-02-05 2025-07-25 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
IL292578A (en) * 2015-02-13 2022-06-01 Sorrento Therapeutics Inc Antibody therapeutics that bind ctla4
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
WO2016164530A1 (en) * 2015-04-07 2016-10-13 University Of Maryland, College Park Compositions and methods for high throughput protein sequencing
ES2927119T3 (es) 2015-04-08 2022-11-02 Sorrento Therapeutics Inc Productos terapéuticos de anticuerpos que se unen a CD38
WO2016205042A1 (en) * 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
MX2018000959A (es) 2015-07-23 2018-06-06 Boehringer Ingelheim Int Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos.
KR20220131277A (ko) * 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
WO2017049011A1 (en) 2015-09-15 2017-03-23 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
CN109071654B (zh) 2015-12-04 2022-09-23 纪念斯隆-凯特琳癌症中心 靶向Fc受体样5的抗体及使用方法
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2018008369A (es) 2016-01-08 2019-05-15 Scholar Rock Inc Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2018009011A (es) 2016-02-02 2018-11-19 Hutchinson Fred Cancer Res Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
JP7152309B2 (ja) 2016-02-17 2022-10-12 シージェン インコーポレイテッド 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用
WO2017184973A1 (en) * 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identifying amyloidogenic proteins & amyloidogenic risk
SMT202000598T1 (it) 2016-06-13 2021-01-05 Scholar Rock Inc Utilizzo di inibitori di miostatina e terapie combinate
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
BR112019000621A2 (pt) * 2016-07-14 2019-04-24 Scholar Rock, Inc. anticorpos tgfss, métodos e usos
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
WO2018039107A1 (en) * 2016-08-22 2018-03-01 Medimmune, Llc Binding molecules specific for notch4 and uses thereof
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
PE20190921A1 (es) 2016-12-07 2019-06-26 Agenus Inc Anticuerpos y metodos de su utilizacion
ES2944357T3 (es) 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
PL3631454T3 (pl) 2017-05-30 2024-01-29 Bristol-Myers Squibb Company Leczenie guzów lag-3 pozytywnych
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
EP4279584A3 (de) 2017-10-16 2024-03-06 Lentigen Technology, Inc. Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd22-immuntherapie
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
ES3035198T3 (en) 2018-03-02 2025-08-29 Elicio Therapeutics Inc Cpg amphiphiles and uses thereof
MA53381A (fr) * 2018-07-24 2021-06-02 Amgen Inc Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
WO2020106886A1 (en) 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
MX2021011181A (es) 2019-03-15 2022-01-19 Morphosys Ag Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos.
EP3941511A2 (de) 2019-03-20 2022-01-26 Massachusetts Institute of Technology Verwendung von amphiphilen in der immunzelltherapie und zusammensetzungen dafür
AU2021253821A1 (en) * 2020-04-08 2022-11-24 Aliada Therapeutics, Inc. Anti-CD98 antibodies and uses thereof
US20230212266A1 (en) * 2020-04-27 2023-07-06 Fred Hutchinson Cancer Center Neutralizing monoclonal antibodies against covid19
MX2022013998A (es) 2020-05-08 2023-02-16 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.
IL301907A (en) 2020-10-23 2023-06-01 Bristol Myers Squibb Co LAG-3 antagonist therapy for lung cancer
WO2022132887A1 (en) * 2020-12-15 2022-06-23 Board Of Regents, The University Of Texas System Human monoclonal antibodies targeting the sars-cov-2 spike protein
US20240270842A1 (en) 2021-05-07 2024-08-15 Viela Bio, Inc Use of an anti-cd19 antibody to treat myasthenia gravis
CA3226744A1 (en) 2021-07-27 2023-02-02 Astrazeneca Ab Treatment of lupus
CN117003872A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
IL318052A (en) * 2022-07-19 2025-02-01 Novartis Ag Treatment of AIHA with BAFF or BAFF RECEPTOR inhibitor antibodies
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
DE68921982T4 (de) 1988-06-14 1996-04-25 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
ES2013978A4 (es) 1988-06-24 1990-06-16 Dow Chemical Co Compuestos de enlace ionico bifuncionales macrociclicos, complejos de ellos y sus anticuerpos conjugados
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
ZA894792B (en) 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (de) 1988-09-02 2008-12-03 Dyax Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (de) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (de) 1990-03-20 1997-10-15 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5635384A (en) 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
ES2129029T5 (es) 1990-10-05 2005-10-16 Celldex Therapeutics, Inc. Inmunoestimulacion dirigida con reactivos biespecificos.
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
EP0517895B1 (de) 1990-12-14 1996-11-20 Cell Genesys, Inc. Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
DE69231223T3 (de) 1991-03-29 2008-01-17 Genentech, Inc., South San Francisco Menschliche pf4a rezeptoren und ihre verwendung
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
ES2093778T3 (es) 1991-04-26 1997-01-01 Surface Active Ltd Nuevos anticuerpos y metodos para su uso.
JPH06510524A (ja) 1991-05-14 1994-11-24 ユニバーシティ オブ コネチカット 免疫原性タンパク質をコードする遺伝子の標的への配達
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
EP0590067A1 (de) 1991-06-14 1994-04-06 Xoma Corporation Mikrobiell hergestellte antikörper-fragmente und deren konjugate
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5376546A (en) 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DK0627940T3 (da) 1992-03-05 2003-09-01 Univ Texas Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1993025788A1 (en) 1992-06-09 1993-12-23 Hoppe Ag Latch and lockset system
US5962301A (en) 1992-06-12 1999-10-05 Massachusetts Institute Of Technology Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
WO1994004670A1 (en) 1992-08-26 1994-03-03 President And Fellows Of Harvard College Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5605671A (en) 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
PT671923E (pt) 1992-10-09 2001-10-30 Advanced Tissue Sciences Inc Celulas de reserva do figado
US5869331A (en) 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5589499A (en) 1992-11-25 1996-12-31 Weth; Gosbert Dopaminergic agents for the treatment of cerebral and peripheral blood flow disorders
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
WO1994020540A1 (es) 1993-03-02 1994-09-15 Universidad De Valladolid PROTEINAS INACTIVADORAS DE RIBOSOMAS (RIPs) DE DOS CADENAS NO TOXICAS, PROCEDIMIENTO PARA SU PREPARACION Y APLICACIONES
EP0717753B1 (de) 1993-09-06 1998-12-02 Menarini Ricerche S.p.A. Ribosom-inaktievirende proteine, die aus saponaria ocymoides und vaccaria pyramidata samen extrahiert sind sowie deren herstellung und immunotoxine, die sie enthalten
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
US5597709A (en) 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5817485A (en) 1994-03-08 1998-10-06 Human Genome Sciences, Inc. Nucleic acids and cells for recombinant production of fibroblast growth factor-10
US5633147A (en) 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
WO1995031468A1 (en) 1994-05-16 1995-11-23 Human Genome Sciences, Inc. Macrophage migration inhibitory factor-3
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
DE69434988T2 (de) 1994-11-07 2008-03-06 Human Genome Sciences, Inc. Tumornekrose-faktor-gamma
DK1323346T3 (da) 1995-01-17 2006-10-30 Brigham & Womens Hospital Receptorspecifik transport af immunogener gennem epitelet
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6635492B2 (en) 1996-01-25 2003-10-21 Bjs Company Ltd. Heating specimen carriers
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CN1214050A (zh) 1996-03-14 1999-04-14 人体基因组科学有限公司 人肿瘤坏死因子δ和ε
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
US5792850A (en) 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2256449A1 (en) 1996-06-06 1997-12-11 Lajolla Pharmaceutical Company Apl immunoreactive peptides, conjugates thereof and methods of treatment for apl antibody-mediated pathologies
IT1286663B1 (it) 1996-06-27 1998-07-15 Ministero Uni Ricerca Scient E Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
CA2263129C (en) 1996-08-16 2007-01-09 Schering Corporation Mammalian cell surface antigens; related reagents
EP0961831B1 (de) 1996-08-16 2008-10-29 Human Genome Sciences, Inc. Menschliches alpha-endokin
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20030175208A1 (en) 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US20020115112A1 (en) 1999-02-23 2002-08-22 Human Genome Sciences, Inc. Neutrokine-alpha and Neutrokine-alpha splice variant
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
WO1999035170A2 (en) 1998-01-05 1999-07-15 Genentech, Inc. Compositions and methods for the treatment of tumor
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
CA2277925A1 (en) 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
DK1012274T4 (da) 1997-01-28 2011-07-25 Human Genome Sciences Inc Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US7803615B1 (en) 1997-03-17 2010-09-28 Human Genome Sciences, Inc. Death domain containing receptor 5
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
EP0970126B1 (de) 1997-04-14 2001-04-18 Micromet AG Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
CA2288351A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1935840A (zh) 1997-05-07 2007-03-28 先灵公司 人Toll样受体蛋白、相关试剂和方法
WO1998054202A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
WO1998055620A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
US6680296B1 (en) 1997-06-06 2004-01-20 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
JP2002517977A (ja) 1997-06-06 2002-06-18 リジェネロン ファーマシューティカルズ，インコーポレイテッド Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
JP2002503963A (ja) 1997-06-11 2002-02-05 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体ｔｒ９
US5948619A (en) 1997-07-31 1999-09-07 Incyte Pharmaceuticals, Inc. Human zygin-1
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US5795724A (en) 1997-09-12 1998-08-18 Incyte Pharmaceuticals, Inc. Human N-acetyl transferase
HUP0004034A3 (en) 1997-09-12 2002-08-28 Apotech R & D Sa Kay - a novel immune system protein
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US20010010925A1 (en) 1997-11-17 2001-08-02 Steven R. Wiley Methods of detecting target nucleic acids of tnf-delta
US20020055624A1 (en) 1997-11-17 2002-05-09 Steven R. Wiley Tnf-delta ligand and uses thereof
WO1999026463A2 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999046295A1 (en) 1998-03-12 1999-09-16 Shanghai Second Medical University A gene homologous to the drosophila b(2)gen gene and putative yeast 26.5kd protein ypr015c
DE69943022D1 (de) 1998-03-19 2011-01-20 Human Genome Sciences Rockville Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
JP3393871B2 (ja) 1998-04-20 2003-04-07 エルエスエス ライフ サポート システムズ アクチエンゲゼルシヤフト 加速度に対する防護服
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
WO2000026244A2 (en) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US6297637B1 (en) * 1998-12-29 2001-10-02 Siemens Aktiengesellschaft High-frequency receiver, particularly for a nuclear magnetic resonance apparatus
ATE437227T1 (de) 1999-01-07 2009-08-15 Zymogenetics Inc Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2
WO2002094852A2 (en) 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
US20050100548A1 (en) 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
PL198934B1 (pl) 1999-01-25 2008-08-29 Apoxis Sa Zastosowanie przeciwciała swoistego wobec rozpuszczalnego BAFF lub aktywnego fragmentu przeciwciała i zastosowanie rozpuszczalnego BAFF lub jego aktywnego fragmentu
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2880400A (en) 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
EP1157110A4 (de) 1999-02-23 2006-05-10 Human Genome Sciences Inc Neutrokin-alpha und Neutrokin-alpha Spleissvarianten
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
CA2382185A1 (en) 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 48 human secreted proteins
EP1806143B1 (de) 1999-08-17 2016-06-15 Biogen MA Inc. BAFF-Rezeptor (BCMA), ein immunregulatorischer Wirkstoff
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2494705A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001234953B2 (en) 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
ATE511857T1 (de) 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
AU5392001A (en) 2000-04-27 2001-11-07 Biogen Inc Taci as an anti-tumor agent
WO2001087979A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1294949A4 (de) 2000-06-15 2004-08-25 Human Genome Sciences Inc Menschlicher tumornekrosefaktor delta und epsilon
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2001097858A2 (en) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
CA2419661A1 (en) 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
EP2270040A3 (de) 2000-08-18 2011-07-06 Human Genome Sciences, Inc. Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
WO2002038766A2 (en) 2000-11-07 2002-05-16 Zymogenetics, Inc. Human tumor necrosis factor receptor
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
JP4002082B2 (ja) 2001-09-14 2007-10-31 古河電気工業株式会社 光ファイバ母材およびその製造方法
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003033658A2 (en) 2001-10-17 2003-04-24 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CA2466229A1 (en) 2001-11-06 2003-10-30 Eli Lilly And Company Use of il-19, il-22 and il-24 to treat hematopoietic disorders
EP1456347A4 (de) 2001-11-16 2006-08-02 Human Genome Sciences Inc Immunspezifisch an blys bindende antikörper
US20020150579A1 (en) 2002-01-10 2002-10-17 Kimberly Robert P. B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus
US20080267965A1 (en) 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
US20050249671A9 (en) 2002-12-23 2005-11-10 David Parmelee Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
WO2004074511A1 (en) 2003-02-21 2004-09-02 Garvan Institute Of Medical Research Diagnosis and treatment of baff-mediated autoimmune diseases and cancer
EP1629001A2 (de) 2003-06-05 2006-03-01 Genentech, Inc. Blys-antagonisten und deren verwendung
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
MXPA06004301A (es) 2003-10-20 2006-06-05 Biogen Idec Inc Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
EP1855711B1 (de) 2005-01-28 2009-06-17 Biogen Idec MA Inc. VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
EP1855724A2 (de) 2005-02-01 2007-11-21 Research Development Foundation Blys-fusionsproteine für targeting des blys-rezeptors und verfahren zur behandlung von proliferativen b-zell-störungen
US20090215071A1 (en) 2005-07-28 2009-08-27 Teresa Cachero Methods of targeting baff
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
RS52888B (sr) 2007-03-27 2014-02-28 Zymogenetics Inc. Kombinacija blys inhibicije i mikofenolat mofetila za lečenje autoimunog obolenja
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EP2582392A4 (de) 2010-06-18 2015-02-18 Human Genome Sciences Inc Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur behandlung von asthma und anderer allergie- oder entzündungsleiden des atemsystems

Also Published As

Publication number Publication date
EP1294769B1 (de) 2011-01-05
AU2009200977B2 (en) 2012-11-15
CY2012003I2 (el) 2020-05-29
EP2275449A1 (de) 2011-01-19
KR20060088905A (ko) 2006-08-07
EP1294769A1 (de) 2003-03-26
CN1492878A (zh) 2004-04-28
US8101181B2 (en) 2012-01-24
US9187548B2 (en) 2015-11-17
PT2281843T (pt) 2017-01-02
MXPA02012434A (es) 2004-09-06
LU91926I2 (fr) 2012-03-05
CA2407910C (en) 2013-03-12
CY1112793T1 (el) 2016-02-10
FR12C0001I2 (fr) 2014-05-16
DK1294769T3 (da) 2011-04-26
ATE494304T1 (de) 2011-01-15
KR101155294B1 (ko) 2013-03-07
CY1118317T1 (el) 2017-06-28
NZ522700A (en) 2006-02-24
DE60143798D1 (de) 2011-02-17
EP1294769A4 (de) 2004-07-28
EP2281843A1 (de) 2011-02-09
CA2407910A1 (en) 2002-01-10
ES2358885T3 (es) 2011-05-16
AU2001268427B2 (en) 2007-03-29
US20030059937A1 (en) 2003-03-27
KR20100133025A (ko) 2010-12-20
US20120121606A1 (en) 2012-05-17
AU6842701A (en) 2002-01-14
EP2275449B1 (de) 2016-09-28
HK1051697A1 (en) 2003-08-15
US7605236B2 (en) 2009-10-20
ES2609583T3 (es) 2017-04-21
WO2002002641A1 (en) 2002-01-10
KR101287395B1 (ko) 2014-11-04
EP2281843B1 (de) 2016-10-12
US20060062789A1 (en) 2006-03-23
ES2609016T3 (es) 2017-04-18
CY2012003I1 (el) 2016-12-14
JP4902618B2 (ja) 2012-03-21
CY1118363T1 (el) 2017-06-28
PT2275449T (pt) 2016-12-27
KR20030038557A (ko) 2003-05-16
JP4902087B2 (ja) 2012-03-21
JP2004509615A (ja) 2004-04-02
KR20120053525A (ko) 2012-05-25
FR12C0001I1 (de) 2012-02-24
CN1279055C (zh) 2006-10-11
EP2281842A1 (de) 2011-02-09
US7138501B2 (en) 2006-11-21
JP2009095346A (ja) 2009-05-07
US20100003259A1 (en) 2010-01-07
AU2009200977A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
BE2012C005I2 (de)
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
DE60236646D1 (de) Anti-VEGF-2 Antikörper
WO2003054216A3 (en) Antibodies that immunospecifically bind to trail receptors
NL300838I2 (de)
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
BR0312768A (pt) Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
WO2003085093A3 (en) Antibodies that specifically bind to gmad
BR0110208A (pt) Composições e terapias para distúrbios associados com hiperlipidemia
KR890011589A (ko) 벤즈아미드의 용도
KR100292396B1 (de)
WO2005016236A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002079377A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003042367A3 (en) Antibodies that immunospecifically bind to trail receptors
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos
WO2002036166A3 (en) Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease